Knowledge and Attitudes Regarding Respiratory Syncytial Virus (RSV) Prevention: A Systematic Review

Vaccines, Journal Year: 2025, Volume and Issue: 13(2), P. 159 - 159

Published: Feb. 6, 2025

Background: New strategies for respiratory syncytial virus (RSV) prevention are available and in development, but their acceptance is crucial to effectiveness. Objectives: This systematic review aims summarize current quantitative qualitative evidence regarding knowledge attitudes relating RSV prevention. Methods: Six databases (PubMed, Scopus, APA PsycArticles; PsycInfo; CINAHL Complete; Psychology Behavioral Sciences Collection) two preprint repositories (medRxiv Preprints) were searched up until 23 December 2024 (PROSPERO: CRD42024602351). Results: Sixty-one articles included, focusing on vaccination the elderly adults at risk (n = 10) or pregnant people 24, of which 8 also examined preferences maternal vs. infant immunization) immunization 27, 16 focused palivizumab, with 6 adherence its monthly administration). Eighteen assessed healthcare professionals. Overall, findings showed limited awareness generally positive towards moderate high intentions uptake rates. Protection against disease perceived severity promoted acceptance, whereas concerns about side effects hindered it. Maternal was more acceptable than immunization. Conclusions: Attitudes options favorable. Should become available, may depend characteristics, how they framed presented. These insights highlight importance education grounded decision-making literature, while recognizing likely favorable reception preventive measures across target age-populations.

Language: Английский

Respiratory syncytial virus immunization with nirsevimab: Acceptance and satisfaction assessment in infants and risk groups in the region of Murcia (Spain)

Human Vaccines & Immunotherapeutics, Journal Year: 2025, Volume and Issue: 21(1)

Published: March 3, 2025

Respiratory syncytial virus (RSV) is a leading cause of respiratory infections in infants under two years age, often resulting bronchiolitis and pneumonia, which contribute to high hospitalization rates. The recent approval nirsevimab, long-acting monoclonal antibody, has provided an immunization alternative for infants, addressing the substantial burden RSV. This study aimed evaluate acceptance satisfaction among parents or legal guardians who were candidates with nirsevimab Region Murcia (Spain) during 2023–2024 campaign. A cross-sectional survey, encompassing 1692 immunized 219 non-immunized revealed rate 87% indicating willingness immunize future child 86.6% willing recommend it. Concerns about safety side effects primary reasons hesitation did not their infants. These findings underscore importance enhancing educational efforts campaigns address concerns, thereby supporting broader RSV coverage pediatric population.

Language: Английский